

**Table 11. Estimated annual costs in Wales**

|   | Number of patients | Cost    |
|---|--------------------|---------|
| <b>Number of people eligible for treatment</b>                                    | <b>10</b>          |         |
| <b>Venetoclax with azacitidine</b>  |                    |         |
| Patients receiving 2 cycles of ven+aza  | 7                  | ¶¶      |
| Patients receiving 5 cycles of ven+aza  | 3                  | ¶¶      |
| Patients proceeding to allogenic HSCT   | 2                  | ¶¶      |
| Adverse events  | 10                 | £9,670  |
| Total cost  |                    | ¶¶      |
| <b>FLAG-Ida</b>   |                    |         |
| Patients receiving 1 cycle of FLAG-Ida  | 7                  | ¶¶      |
| Patients receiving 2 cycles of FLAG-Ida*  | 3                  | ¶¶      |
| Patients proceeding to allogenic HSCT   | 5                  | ¶¶      |
| Adverse events  | 10                 | £11,460 |
| Total cost  |                    | ¶¶      |
| <b>Annual net cost</b>  |                    | ¶¶      |
| *Second cycle FLAG without idarubicin<br>¶¶ commercial in confidence data removed |                    |         |